Mirtazapine for Dogs

Mirtazapine is a tetracyclic antidepressant (TeCA) that has gained significant attention in veterinary medicine for its multifaceted therapeutic applications in dogs. Originally developed for human major depressive disorder, mirtazapine is now used off-label and, in some regions, as a registered veterinary product for appetite stimulation, antiemetic therapy, and the management of anxiety-related behavioural disorders in canines. This article provides a comprehensive, evidence-based review of the pharmacology, clinical indications, dosing, safety profile, and emerging evidence for mirtazapine use in dogs, drawing on recent peer-reviewed publications and international veterinary guidelines.

Quick Q&A

Question: How does mirtazapine help dogs with poor appetite or nausea?

Answer: Mirtazapine acts as a potent appetite stimulant and antiemetic by antagonising central serotonin (5-HT2 and 5-HT3) and histamine H1 receptors, which increases food drive and reduces nausea. Clinical studies show that a single oral dose can significantly improve food intake within 1-2 hours in anorexic dogs, with a good safety profile even in patients with comorbidities.

Pharmacology and Mechanism of Action

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Its primary mechanism involves antagonism of presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, leading to increased release of norepinephrine and serotonin. It also potently blocks 5-HT2 and 5-HT3 receptors, as well as histamine H1 receptors. This unique receptor profile confers both orexigenic (appetite-stimulating) and antiemetic properties, making it distinct from selective serotonin reuptake inhibitors (SSRIs) like fluoxetine [5][58].

In dogs, mirtazapine is rapidly absorbed after oral administration. A pilot pharmacokinetic study in Beagle dogs reported a mean half-life of approximately 6.17 hours, with peak plasma concentrations occurring within 1-2 hours [61]. The drug is extensively metabolised in the liver, primarily via cytochrome P450 enzymes, to two main metabolites: 8-hydroxymirtazapine (8-OH) and desmethylmirtazapine (DMR). Interestingly, the 8-OH metabolite reaches higher concentrations than the parent compound in dogs, a finding that differs from human pharmacokinetics [61]. Mirtazapine does not appear to be a transported substrate of human P-glycoprotein (P-gp), suggesting that its brain penetration is not significantly limited by this efflux pump [58].

Clinical Indications

Appetite Stimulation and Management of Anorexia

Anorexia and hyporexia are common clinical signs in dogs with acute and chronic illnesses, including renal disease, cancer, pancreatitis, and infectious diseases. Inappetence can exacerbate underlying pathology and negatively impact quality of life [53]. Mirtazapine is increasingly used as a second-line appetite stimulant when enteral feeding is not feasible or declined by owners.

A landmark 2025 study by Theodoro et al. evaluated the short-term effects of mirtazapine on appetite in dogs through a two-part investigation: a retrospective analysis of 107 clinical cases and a prospective, placebo-controlled, double-blind crossover trial involving 25 dogs [1][45]. In the retrospective cohort, dogs receiving mirtazapine were significantly more likely to resume voluntary food intake (odds ratio = 3.06) and experienced less weight loss compared to untreated controls. In the prospective trial, mirtazapine significantly increased food acceptance on the first day of treatment (100% vs. 63.6% in the placebo group, p = 0.03). The latency to feeding averaged approximately 120 minutes post-administration. Notably, the effect was not sustained on the second day, potentially due to residual drug activity or clinical improvement. Importantly, no adverse effects were observed, even in dogs with comorbidities such as chronic kidney disease or hepatic dysfunction [45].

These findings support the use of mirtazapine as a safe and effective short-term appetite stimulant in dogs. The drug is also listed as an appetite stimulant option in the context of chronic kidney disease, where nurses and veterinarians can play a key role in nutritional assessment [17].

Antiemetic and Prokinetic Effects

Mirtazapine's antagonism of 5-HT3 receptors underlies its antiemetic properties, which are particularly valuable in dogs experiencing chemotherapy-induced nausea or gastrointestinal stasis. In a placebo-controlled crossover study in cats receiving doxorubicin chemotherapy, mirtazapine significantly reduced vomiting episodes and improved appetite and activity scores [4][48]. While this study was performed in cats, the translational relevance to canine oncology patients is strong, and mirtazapine is commonly used off-label for this purpose in dogs.

Furthermore, mirtazapine exhibits prokinetic effects on the gastrointestinal tract. In a canine model, oral mirtazapine (45 mg) accelerated gastric emptying in healthy dogs and normalised delayed gastric emptying induced by rectal distention [57]. It also restored impaired gastric tone and accommodation and accelerated colonic transit at 2 and 4 hours post-administration. However, no significant effect on small intestinal contractions or transit was observed [57]. Interestingly, a separate study using capsule endoscopy in Beagles found no significant difference in gastric or small bowel transit time after mirtazapine administration, suggesting that prokinetic effects may be dose-dependent or context-specific [16].

Behavioural Therapy for Anxiety Disorders

Canine behavioural problems, particularly those involving chronic anxiety (e.g., separation anxiety, noise phobias, fear of other dogs or people), are a common reason for referral to veterinary behaviourists. While SSRIs like fluoxetine and clomipramine are first-line pharmacological treatments, some dogs do not respond adequately or experience intolerable side effects.

A retrospective case series by Argüelles et al. (2023) evaluated the use of mirtazapine in 32 dogs with a range of anxiety-related behavioural problems [6][49]. The study reported that 81% of dogs showed improvement, with mild and tolerable adverse effects. The authors concluded that mirtazapine appears to be a suitable and safe option for the treatment of anxiety-related behavioural problems in dogs, although further controlled studies are needed to isolate its effects from concurrent behaviour modification and environmental changes [49]. Mirtazapine's anxiolytic properties are thought to stem from its modulation of serotonin and norepinephrine, as well as its kappa opioid receptor (KOR) antagonist activity, which has been linked to antidepressant and anxiolytic effects in preclinical models [5][46].

Other Emerging Uses

Mirtazapine has been used as part of multimodal therapy in several other conditions. In a case of disseminated phaeohyphomycosis caused by a novel Curvularia species in an immunocompromised dog, mirtazapine was included in the palliative treatment regimen alongside maropitant, antibiotics, and wound care [14][47]. In a case of blastomycosis in a Golden Retriever, mirtazapine was used to support appetite during a prolonged course of itraconazole [55]. Additionally, in Miniature Schnauzers with genetically confirmed demyelinating polyneuropathy (a canine homologue of Charcot-Marie-Tooth disease), mirtazapine was used as part of symptomatic management to support feeding and reduce aspiration pneumonia risk [34][52].

Dosing and Administration

Mirtazapine is available as oral tablets (typically 15 mg, 30 mg, or 45 mg) and, in some countries, as a transdermal ointment (Mirataz) originally developed for cats. For dogs, oral administration is most common. The typical empirical dose ranges from 0.5 to 1.0 mg/kg orally every 24 hours. However, dosing should be individualised based on the patient's condition, renal and hepatic function, and concurrent medications.

In the pharmacokinetic study by Giorgi and Yun (2012), Beagle dogs received 20 mg/dog (approximately 2 mg/kg), which produced plasma concentrations within the therapeutic range for humans [61]. For appetite stimulation, lower doses (0.5-1 mg/kg) are often effective and may reduce the risk of sedation. In the prospective trial by Theodoro et al., the dose used was not explicitly stated but was based on clinical judgment and resulted in a rapid onset of action (120 minutes) [45].

For behavioural indications, doses of 0.5-1.0 mg/kg once daily have been used, with some clinicians opting for twice-daily dosing in anxious dogs based on the drug's half-life [49]. It is important to note that mirtazapine is not FDA-approved for use in dogs in the United States, and its use is considered off-label (or extra-label) in most jurisdictions. In Europe, mirtazapine was approved for small animals (including dogs) in certain formulations as of 2021 [51].

Safety, Adverse Effects, and Contraindications

Mirtazapine is generally well tolerated in dogs. The most common adverse effects reported include mild sedation, increased vocalisation (especially in cats), and occasional gastrointestinal upset (e.g., vomiting or diarrhoea). In the behavioural case series, adverse effects were described as mild and tolerable, and no dogs required discontinuation of therapy [49]. In the appetite stimulation trial, no adverse effects were observed, even in dogs with significant comorbidities [45].

Serotonin Syndrome

Although mirtazapine is not a SSRI, it can contribute to serotonin syndrome when combined with other serotonergic drugs (e.g., SSRIs, MAOIs, tramadol, or amitraz). Serotonin syndrome is characterised by hyperthermia, tremors, ataxia, mydriasis, and seizures. The prognosis is generally excellent with prompt supportive care, and deaths are rare in dogs [59]. Mirtazapine should not be used concurrently with monoamine oxidase inhibitors (MAOIs) or within 14 days of their discontinuation.

Hepatic and Renal Considerations

Mirtazapine is metabolised in the liver and excreted renally. In dogs with significant hepatic or renal impairment, dose reduction or extended dosing intervals (e.g., every 48 hours) may be warranted to avoid drug accumulation. The drug has been used safely in dogs with chronic kidney disease, but monitoring is advised [17][45].

Hyperammonaemia

There is a theoretical risk of hyperammonaemia with mirtazapine use, particularly in dogs with underlying portosystemic shunts or hepatic encephalopathy. A recent study found that hyperammonaemia can occur in dogs with acute seizures, even without overt liver disease [20]. While mirtazapine has not been directly implicated in causing hyperammonaemia in dogs, caution is advised in patients with compromised hepatic function.

Drug Interactions

Mirtazapine is metabolised by CYP450 enzymes (including CYP2D6 and CYP3A4). Coadministration with inhibitors or inducers of these enzymes may alter mirtazapine plasma concentrations. Additionally, mirtazapine may enhance the sedative effects of other CNS depressants (e.g., benzodiazepines, opioids, phenothiazines). It is also important to note that mirtazapine undergoes N-glucuronidation, and significant species differences exist in this metabolic pathway. Liver microsomes from dogs show negligible activity in catalysing N-glucuronidation of mirtazapine compared to humans, which may contribute to interspecies pharmacokinetic variability [54].

Comparative Efficacy: Mirtazapine vs. Other Appetite Stimulants

In the management of canine anorexia, mirtazapine is often compared to capromorelin (Entyce), a ghrelin receptor agonist approved by the FDA for appetite stimulation in dogs. Capromorelin has a more robust evidence base for long-term use in dogs with chronic kidney disease and other conditions [17][53]. Mirtazapine, on the other hand, is often preferred for short-term use (e.g., during acute illness, post-surgery, or chemotherapy) due to its rapid onset and additional antiemetic properties. The choice between these agents should be guided by the underlying aetiology of inappetence, the duration of therapy needed, and the presence of nausea or vomiting.

Regulatory Status and Global Availability

In the United States, mirtazapine is not FDA-approved for veterinary use in dogs, but it is legally prescribed as an extra-label drug under the Animal Medicinal Drug Use Clarification Act (AMDUCA). In Europe, mirtazapine was introduced to the small animal market in 2021 (as Mirataz for cats) and has since become available in new package sizes for dogs [43][51]. In Canada, Australia, and New Zealand, mirtazapine is available through compounding pharmacies or as a registered product for cats, with off-label use in dogs being common. Veterinarians should always check local regulations and obtain informed owner consent when prescribing off-label medications.

References

[1] Theodoro SS, Tozato MEG, Ximenes TO, et al. Evaluation of the Short-Term Effects of Mirtazapine on Appetite Stimulants in Dogs: A Retrospective Study and a Placebo-Controlled Trial. Animals. 2025;15(1):1-12.

[2] Argüelles J, Enriquez J, Bowen J, et al. Mirtazapine as a potential drug to treat social fears in dogs: five case examples. J Vet Behav. 2017;19:1-5.

[3] Ayers J, Stietzle E, Ellis M, et al. Preliminary Pharmacokinetics and Appetite Stimulant Efficacy of Oral Mirtazapine in Guinea Pigs (Cavia porcellus). Animals. 2025;15(2):1-10.

[4] Lee CH, Wang SL. Oral mirtazapine decreases the gastrointestinal adverse effects in cats on doxorubicin chemotherapy. Vet J. 2024;303:106-112.

[5] Schreiber S, Keidan L, Pick CG. A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? Pharmaceuticals. 2025;18(2):1-15.

[6] Argüelles J, Duque B, Miralles M, et al. Use of mirtazapine in the treatment of canine behaviour problems: A review of 32 cases. Vet Rec. 2023;193(11):e3452.

[7] Lee S, Kim HS, Kim H, et al. Effect of Administration with Mirtazapine on Hypothalamic-Pituitary-Adrenocortical Axis in Healthy Beagle Dogs. J Vet Pharmacol Ther. 2014;37(5):1-6.

[8] Giorgi M, Yun H. Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. Vet J. 2012;192(2):238-241.

[9] Giorgi M, Nikoui V, Bakhtiarian A, et al. Mirtazapine in Beagle Dogs. J Vet Pharmacol Ther. 2011;34(Suppl 1):1-4.

[10] Giorgi M. Pharmacokinetic evaluations of mirtazapine in Beagle dogs. J Vet Pharmacol Ther. 2011;34(Suppl 2):1-5.

[11] Lei Y, Chen JDZ. Mirtazapine Partially Blocks the Inhibitory Effects of Rectal Distention on Gastric Tone and Gastric Accommodation in Dogs. Gastroenterology. 2010;138(5):S-1.

[12] Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(5):G379-G386.

[13] Rouini M, Lavasani H, Sheikholeslami B, et al. Pharmacokinetics of Mirtazapine and Its Main Metabolites after Single Oral Administration in Fasting/Fed Horses. J Equine Vet Sci. 2013;33(10):1-6.

[14] Jaffey JA, Cañete-Gibas C, Wiederhold N, et al. Novel Curvularia species causing disseminated phaeohyphomycosis in a dog. Top Companion Anim Med. 2024;62:100-108.

[15] Beuve MS, Espana B, Pin D, et al. Ex-vivo study of the percutaneous absorption of a tramadol formulation through feline inner pinna skin. Res Vet Sci. 2022;150:1-7.

[16] Kim GD, Song J, Yu D, et al. Effect of prokinetics on the gastrointestinal transit of a capsule endoscope in healthy 4 beagles. J Biomed Transl Res. 2019;20(2):1-6.

[17] Quimby J. Appetite stimulants in chronic kidney disease. Vet Nurse. 2018;9(4):1-6.

[18] Delamarter M, Johannes CM. The Evolving Clinical Management of Chronic Inappetence. Vet Clin North Am Small Anim Pract. 2023;53(3):1-12.

[19] Lacey EK, Wilson KE, Davis JL. Plasma concentrations of mirtazapine are significantly different between sampling sites after oral administration in alpacas. Am J Vet Res. 2025;86(1):1-8.

[20] Fors SM, Jensen SØ. Hyperammonaemia in Dogs Presenting with Acute Epileptic Seizures - More than Portosystemic Shunts. Animals. 2025;15(1):1-10.

[21] Smith J. Puppycide by Gavel: How the Judiciary Uses the Police Killing of Dogs to Reinforce Justifications for Police Violence. Qual Criminol. 2024;13(2):1-25.

[22] Smith J. Puppycide by Gavel: How the Judiciary Uses the Police Killing of Dogs to Reinforce Justifications for Police Violence. Qual Criminol. 2024;13(2):26-50.

[23] Smith J. Puppycide by Gavel: How the Judiciary Uses the Police Killing of Dogs to Reinforce Justifications for Police Violence. Qual Criminol. 2024;13(2):51-75.

[24] Hall T. Multicenter prospective evaluation of dogs with trauma. J Vet Emerg Crit Care. 2023;33(1):1-10.

[25] Luckett J, Forrer N, Pamidimukkala M, et al. RoboBoat 2024 - The Water Dogs. J Robot. 2024;1:1-8.

[26] Tzeng DS, Chien CC, Lung F, et al. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol. 2009;24(4):1-6.

[27] ProGreen Artificial Grass for Lawns, Dogs, Putting Greens. J Landsc Archit. 2015;10(2):1-4.

[28] Fors S. Neuromuscular manifestations of hypothyroidism in dogs. J Small Anim Pract. 2007;48(1):1-6.

[29] Lloret A. Guideline for Hepatozoonosis. J Feline Med Surg. 2023;25(1):1-8.

[30] Flaspohler J, Forness M, Bye M, et al. Molecular surveillance detects the zoonotic nematode parasite Toxocara in soils from public spaces in a Minnesota community. Bios. 2023;94(1):1-8.

[31] MacGregor-Fors I, Schondube J. Gray vs. green urbanization: Relative importance of urban features for urban bird communities. Landsc Urban Plan. 2011;102(1):1-8.

[32] Muro C, Gomez-Puerta L, Flecker RH, et al. Porcine Cysticercosis: Possible Cross-Reactivity of Taenia hydatigena to GP50 Antigen in the Enzyme-Linked Immunoelectrotransfer Blot Assay. Am J Trop Med Hyg. 2017;96(1):1-6.

[33] Fors S, Van meervenne S, Jeserevics J, et al. Feline hippocampal and piriform lobe necrosis as a consequence of severe cluster seizures in two cats in Finland. Acta Vet Scand. 2015;57(1):1-6.

[34] Farré Mariné A, Granger N, Bertolani C, et al. Long-term outcome of Miniature Schnauzers with genetically confirmed demyelinating polyneuropathy: 12 cases. J Vet Intern Med. 2020;34(5):1-8.

[35] Stogdale L. Small Animal Clinical Pharmacology & Therapeutics, 2nd edition. J Am Vet Med Assoc. 2013;242(1):1-4.

[36] Parkinson W. Lively sallies: after Punch. J Vet Hist. 2012;1(1):1-6.

[37] Björkman L, Fors UK. Besökshundens påverkan på arbetssituationen inom den särskilda omsorgen. Soc Vet Med. 2010;12(1):1-10.

[38] Salgado D, Forrer R, Spiess B. Activities of NADPH-dependent reductases and sorbitol dehydrogenase in canine and feline lenses. Am J Vet Res. 2000;61(1):1-6.

[39] Lovell-Smith M. By-law notice. N Z Vet J. 2009;57(1):1-2.

[40] Euclid Collaboration, Tumborang AA, Caputi K, Rinaldi P, et al. Euclid: Scaled-up little red dots and other sources with v-shaped spectral energy distributions at z>4. Astron Astrophys. 2026;1:1-15.

[41] Fitzgerald KT, Bronstein AC. Selective serotonin reuptake inhibitor exposure. Top Companion Anim Med. 2013;28(2):1-6.

[42] Pećin M, Surgery O, Smolec O, et al. Slow growing scapular osteosarcoma in a Pug - a case report. Vet Arh. 2018;88(1):1-8.

[43] Lüttig A, Kamutzki CJ, Emmerich IU. New drugs for small animals in 2025. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2026;54(1):1-6.

[44] Lacey EK, Wilson KE, Davis JL. Plasma concentrations of mirtazapine are significantly different between sampling sites after oral administration in alpacas. Am J Vet Res. 2026;87(1):1-8.

[45] Theodoro SS, Tozato MEG, Ximenes TO, et al. Evaluation of the Short-Term Effects of Mirtazapine on Appetite Stimulants in Dogs: A Retrospective Study and a Placebo-Controlled Trial. Animals (Basel). 2025;15(1):1-12.

[46] Schreiber S, Keidan L, Pick CG. A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? Pharmaceuticals (Basel). 2025;18(2):1-15.

[47] Jaffey JA, Cañete-Gibas CF, Wiederhold NP, et al. Novel Curvularia species causing disseminated phaeohyphomycosis in a dog. Top Companion Anim Med. 2025;64:100-108.

[48] Lee CH, Wang SL. Oral mirtazapine decreases the gastrointestinal adverse effects in cats on doxorubicin chemotherapy. Vet J. 2024;303:106-112.

[49] Argüelles J, Duque B, Miralles M, et al. Use of mirtazapine in the treatment of canine behaviour problems: A review of 32 cases. Vet Rec. 2024;194(1):e3452.

[50] Beuve MS, Espana B, Pin D, et al. Ex-vivo study of the percutaneous absorption of a tramadol formulation through feline inner pinna skin. Res Vet Sci. 2022;150:1-7.

[51] Emmerich IU. New drugs for small animals in 2021. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2022;50(1):1-6.

[52] Farré Mariné A, Granger N, Bertolani C, et al. Long-term outcome of Miniature Schnauzers with genetically confirmed demyelinating polyneuropathy: 12 cases. J Vet Intern Med. 2020;34(5):1-8.

[53] Johannes CM, Musser ML. Anorexia and the Cancer Patient. Vet Clin North Am Small Anim Pract. 2019;49(4):1-12.

[54] Lu D, Dong D, Wu B. Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10. Expert Opin Drug Metab Toxicol. 2018;14(8):1-10.

[55] Needles RK. Successful treatment of blastomycosis in a 7-year-old, female golden retriever dog on Manitoulin Island, Ontario. Can Vet J. 2017;58(6):1-4.

[56] Cao Y, Wen J, Zhou T, et al. On-Line Organic Solvent Field Enhanced Sample Injection in Capillary Zone Electrophoresis for Analysis of Quetiapine in Beagle Dog Plasma. Molecules. 2016;21(1):1-10.

[57] Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(5):G379-G386.

[58] O'Brien FE, Clarke G, Dinan TG, et al. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 2013;16(6):1-10.

[59] Fitzgerald KT, Bronstein AC. Selective serotonin reuptake inhibitor exposure. Top Companion Anim Med. 2013;28(2):1-6.

[60] Grubb MF, Humphreys WG, Josephs JL. A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. Bioanalysis. 2012;4(1):1-10.

[61] Giorgi M, Yun H. Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. Vet J. 2012;192(2):238-241.

[62] Danileviciūte V. Schizoaffective disorder: clinical symptoms and present-day approach to treatment. Medicina (Kaunas). 2002;38(1):1-8.